Last updated: 17 July 2019 at 4:02pm EST

Capital Iii Lp Aisling Capi... Net Worth




The estimated Net Worth of Capital Iii Lp Aisling Capi... is at least $314 Million dollars as of 10 July 2018. Capital Capi owns over 1,400,000 units of T2 Biosystems Inc stock worth over $4,689,516 and over the last 9 years Capital sold TTOO stock worth over $308,827,000.

Capital Capi TTOO stock SEC Form 4 insiders trading

Capital has made over 8 trades of the T2 Biosystems Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Capital sold 1,400,000 units of TTOO stock worth $251,202,000 on 10 July 2018.

The largest trade Capital's ever made was selling 1,400,000 units of T2 Biosystems Inc stock on 10 July 2018 worth over $251,202,000. On average, Capital trades about 406,306 units every 118 days since 2015. As of 10 July 2018 Capital still owns at least 2,038,920 units of T2 Biosystems Inc stock.

You can see the complete history of Capital Capi stock trades at the bottom of the page.



Insiders trading at T2 Biosystems Inc

Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ..., and Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.



What does T2 Biosystems Inc do?

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www



Complete history of Capital Capi stock trades at Syros Pharmaceuticals and T2 Biosystems Inc

Insider
Trans.
Transaction
Total value
Capital Iii Lp Aisling Capi...
Buy $5,000,000
6 Jul 2016
Capital Iii Lp Aisling Capi...
Buy $2,999,997
9 Dec 2015


T2 Biosystems Inc executives and stock owners

T2 Biosystems Inc executives and other stock owners filed with the SEC include: